OXFORD,
England and CAMBRIDGE,
Mass., June 18, 2024 /PRNewswire/ -- SpyBiotech,
a biotechnology company with a novel vaccine platform technology
that can target infectious diseases, cancer, and chronic diseases,
has appointed Keith Dewedoff as
Chief Financial Officer (CFO).
Keith brings more than 20 years of experience in the life
science industry to SpyBiotech, ranging from biotech venture-backed
start-ups to commercial publicly traded companies. Keith also
serves as a CFO and Advisor for Danforth Advisors, an advisory firm
focused on providing financial strategy to life science
organizations. He previously served as CFO of Ceptur Therapeutics
and more than 10 other privately held and public companies at
various life cycle stages. His responsibilities included managing
finance, accounting, corporate development, and other corporate
operational functions. Prior to Danforth, Keith was CFO of Kaizen
Bioscience where he is still active on the board as Chair and also
serves as a venture partner at an early-stage incubator focused on
infectious diseases. Keith earned a Bachelor of Science in
Economics from Northeastern University
and studied graduate work at Oxford University.
"I am proud to join the SpyBiotech team as the company continues
to expand," said Keith Dewedoff.
"Given the recently announced research collaboration with the
University of Oxford and SpyBiotech's
Phase I trial of its HCMV vaccine, this is a really exciting time
to join the company."
"Keith is an excellent addition to our leadership team. His
depth of expertise in financial strategy and corporate development
will serve SpyBiotech well as we continue to build our organization
and progress our scientific pipeline," said Mark Leuchtenberger, Chief Executive Officer.
"We look forward to this new chapter of advancement with our lead
candidate in the clinic and our EBV-focused collaboration with the
University of Oxford."
About SpyBiotech
SpyBiotech is a clinical stage biotechnology company with novel
vaccine platform technologies to target infectious diseases, cancer
and chronic diseases. The company was spun out of the University of Oxford in 2017 by Oxford Science
Enterprises (OSE) and Google Ventures (GV). The company raised
$32.5 million in a Series A equity
financing in 2021. Based on science developed at the University of Oxford, SpyBiotech's novel vaccine
platform is based on a proprietary protein "superglue" technology
which binds antigens to vaccine delivery platforms in a way which
minimizes delivery risk and enhances immunogenicity and efficacy.
This makes it ideal for use against infectious diseases in
challenging environments, such as in the developing world, but also
with potential application in non-infectious disease settings such
as cancer. SpyBiotech has the exclusive rights from the
University of Oxford to apply,
commercialize and sub-license the SpyTag/SpyCatcher and related
"superglue" technologies in vaccine development.
View original
content:https://www.prnewswire.com/news-releases/spybiotech-appoints-keith-dewedoff-as-new-chief-financial-officer-302174546.html
SOURCE SpyBiotech